Home News Deals, joint ventures & alliances

New Silkroutes Group signs MOU with Huawei to develop AI platform for genomics-driven healthcare

Felicia Tan
Felicia Tan1/18/2021 06:37 PM GMT+08  • 2 min read
New Silkroutes Group signs MOU with Huawei to develop AI platform for genomics-driven healthcare
Shares in NSG closed 0.3 cent higher or 4% up at 7.8 cents on Jan 18.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

New Silkroutes Group Limited (NSG) has signed a memorandum of understanding (MOU) with Huawei International to develop an artificial intelligence (AI) platform that can be used in genomics-driven healthcare.

Under the MOU, NSG and Huawei will explore a collaboration to use AI to establish breakthrough analyses into genomic data and develop predictive models for cancel and genomics.

Genomic medicine involves the study of a patient’s DNA and how the information can be used to improve clinical care through better diagnosis and personalised treatment.

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.
Unlock unlimited access to premium articles with less than $9 per month. Subscribe Now